• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

MedCap

481.20 SEK

+0.50 %

Less than 1K followers

MCAP

NASDAQ Stockholm

Investment

Financials

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.50 %
-14.91 %
+5.41 %
-12.35 %
-13.45 %
+15.12 %
+76.91 %
+134.73 %
+4,664.36 %

MedCap operates in the investment industry and focuses on long-term equity investments in medical technology and pharmaceutical companies. The company's portfolio includes companies in sectors such as biotechnology and medical technology. The operations are primarily concentrated in Sweden, with a primary presence in the Stockholm region. MedCap was founded in 2001 and is headquartered in Stockholm.

Read more
Market cap
7.26B SEK
Turnover
4.18M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
21.7.
2026

Interim report Q2'26

23.10.
2026

Interim report Q3'26

5.2.
2027

Annual report '26

Press release5/5/2026, 6:53 AM

Redeye: MedCap (Q1 review): Strong EBITA Growth, Poised for Acquisitions

MedCap
Regulatory press release4/29/2026, 4:30 AM

Strong result; EBITA increased by 30%

MedCap
Press release2/11/2026, 12:33 PM

Redeye: MedCap (Q4 review): Beat on Solid Organic Growth

MedCap

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release2/6/2026, 5:30 AM

Strong results: EBITA increased by 68% for the quarter and 26% for the full year

MedCap
Press release10/27/2025, 1:26 PM

Redeye: MedCap (Q3 review) - Healthy Q3 figures

MedCap
Regulatory press release10/24/2025, 4:30 AM

MedCap AB: Strong organic and acquired growth; EBITA increased by 32%

MedCap
Regulatory press release10/1/2025, 1:00 PM

MedCap AB: Abilia acquires LivAssured

MedCap
Press release7/23/2025, 12:05 PM

Redeye: MedCap Q2 2025 - The rise, fall, and rise again

MedCap
Regulatory press release7/23/2025, 4:30 AM

MedCap AB: Strong quarter with 20 percent EBITA growth and acquisition in Specialty Pharma

MedCap
Regulatory press release7/21/2025, 10:00 AM

MedCap AB: MedCap's Business Area Specialty Pharma Completes the Acquisition of XGX Pharma

MedCap
Regulatory press release6/25/2025, 5:30 AM

MedCap AB: MedCap's Business Area Specialty Pharma Acquires XGX Pharma

MedCap
Press release4/30/2025, 5:47 AM

Redeye: MedCap Q1 2025 - Step by step

MedCap
Regulatory press release4/29/2025, 4:30 AM

MedCap AB: 7% growth and EBITA margin recovers to 17%

MedCap
Press release2/3/2025, 7:53 AM

Redeye: MedCap Q4 2024 - A tale of euphoria and despair

MedCap
Regulatory press release1/31/2025, 5:30 AM

MedCap AB: Good demand but unsatisfactory earnings. Strong cash flow.

MedCap
Regulatory press release1/31/2025, 5:30 AM

MedCap AB: MedCap's Business Area Assistive Tech Acquires Danrehab

MedCap
Regulatory press release1/16/2025, 5:30 PM

MedCap AB: Preliminary result for the fourth quarter

MedCap
Press release11/4/2024, 9:24 AM

Redeye: Redeye Initiates Coverage of MedCap

MedCap
Regulatory press release10/25/2024, 4:30 AM

MedCap AB: Profit growth, stronger cash flow and acquisitions

MedCap
Regulatory press release7/24/2024, 4:30 AM

MedCap AB: Continued strong growth - adjusted EBITA increased by 13 percent

MedCap